View more in
Cancer

Lisaftoclax Shows Early Safety, Efficacy in Relapsed/Refractory CLL/SLL and Other Hematologic Cancers

onclive.com
 2021-06-07

The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers. The novel BCL-2 inhibitor lisaftoclax (APG-2575) elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and...

www.onclive.com

Comments / 0

Comments / 0